# Overestimation of anticoagulant benefit in patients with atrial fibrillation and low

## life expectancy: evidence from 12 randomized trials

Sachin J. Shah, MD, MPH (1); Carl van Walraven, MD, MSc (2); Sun Young Jeon, PhD (3); W.

John Boscardin, PhD (3, 4); FD Richard Hobbs, FMedSci (5), Stuart Connolly, MD (6); Michael

Ezekowitz MB, ChB, DPhil (7); Kenneth E. Covinsky, MD, MPH (3); Margaret C. Fang, MD,

MPH (3), Daniel E. Singer, MD (1)

- (1) Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- (2) Departments of Medicine and Epidemiology & Community Medicine, University of Ottawa, Ottawa ON, CA
- (3) Department of Medicine, University of California San Francisco, San Francisco, CA, USA
- (4) Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA
- (5) Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford UK
- (6) Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- (7) Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA and Cardiovascular Medicine, Lankenau Institute for Medical Research, Wynnewood, PA, USA

Corresponding Author

Sachin J. Shah, MD, MPH

100 Cambridge Street, Suite 1600

Boston, MA 02114

sshah@mgh.harvard.edu

617-977-4871

Manuscript: 2939 words

Abstract: 320 words

Preprint (medRxiv): https://doi.org/10.1101/2023.02.10.23285303

#### 1 ABSTRACT

Background: Patients with atrial fibrillation (AF) have a high rate of all-cause mortality that is
only partially attributable to vascular outcomes. While the competing risk of death may affect
expected anticoagulant benefit, guidelines do not account for it. We sought to determine if using
a competing risks framework materially affects the guideline-endorsed estimate of absolute risk
reduction attributable to anticoagulants.

7 **Methods**: We conducted a secondary analysis of 12 RCTs that randomized patients with AF to 8 oral anticoaculants or either placebo or antiplatelets. For each participant, we estimated the 9 absolute risk reduction (ARR) of anticoagulants to prevent stroke or systemic embolism using 10 two methods. First, we estimated the ARR using a guideline-endorsed model (CHA<sub>2</sub>DS<sub>2</sub>-VASc) and then again using a Competing Risk Model that uses the same inputs as CHA<sub>2</sub>DS<sub>2</sub>-VASc but 11 12 accounts for the competing risk of death and allows for non-linear growth in benefit over time. 13 We compared the absolute and relative differences in estimated benefit and whether the 14 differences in estimated benefit varied by life expectancy.

15 **Results:** 7933 participants had a median life expectancy of 8 years (IQR 6, 12), determined by comorbidity-adjusted life tables. 43% were randomized to oral anticoagulation (median age 73 16 17 years, 36% women). The guideline-endorsed CHA<sub>2</sub>DS<sub>2</sub>-VASc model estimated a larger ARR 18 than the Competing Risk Model (median ARR at 3 years, 6.9% vs. 5.2%). ARR differences varied by life expectancies: for those with life expectancies in the highest decile, 3-year ARR 19 20 difference (CHA<sub>2</sub>DS<sub>2</sub>-VASc model – Competing Risk Model 3-year risk) was -1.2% (42% 21 relative underestimation); for those with life expectancies in the lowest decile, 3-year ARR 22 difference was 5.9% (91% relative overestimation).

Conclusion: Anticoagulants were exceptionally effective at reduced stroke risk. However,
 anticoagulant benefits were misestimated with CHA<sub>2</sub>DS<sub>2</sub>-VASc, which does not account for the

- 25 competing risk of death nor decelerating treatment benefit over time. Overestimation was most
- 26 pronounced in patients with the lowest life expectancy and when benefit was estimated over a
- 27 multi-year horizon.

## 28 INTRODUCTION

29 Anticoagulants are the mainstay of preventative therapy for millions of older adults with atrial fibrillation. While anticoagulants reduce the risk of ischemic stroke and systemic embolism, 30 they also increase the risk of bleeding. To help patients and clinicians weigh the risks and 31 32 benefits of treatment, clinical guidelines and decision support tools endorse using the CHA<sub>2</sub>DS<sub>2</sub>-33 VASc score to estimate a patient's annual risk of ischemic stroke or systemic embolism without treatment.<sup>1-5</sup> The ACC/AHA/HRS consensus guidelines recommend that this baseline risk be 34 35 used to estimate a patient's expected absolute risk reduction by applying the relative risk reduction from a meta-analysis of randomized trials.<sup>1,6</sup> Guidelines recommend anticoagulant 36 therapy when the absolute risk reduction exceeds a threshold. The premise is that treatment 37 benefits outweigh risks when an individual's estimated event risk exceeds this threshold. 38

39 While transparent, this approach makes two assumptions that can affect the accuracy of expected benefit. First, this approach does not account for the competing risk of death. A 40 competing risk is an alternative outcome that occurs before, and necessarily precludes, the 41 42 event of interest (e.g., cancer death before stroke from atrial fibrillation), thus limiting the absolute benefit achievable by anticoagulant treatment.<sup>7–11</sup> Competing risks are germane given 43 the high all-cause mortality rate following a new diagnosis of atrial fibrillation-multiple studies 44 estimate 20-25% mortality in the first year.<sup>12-14</sup> Second, this approach assumes that the 45 therapeutic benefit continues to increase at a constant rate over time-that is, the risk of stroke 46 47 over two years is twice the one-year risk and thus the absolute risk reduction over two years is twice the one-year absolute risk reduction. Both issues are readily addressed by estimating 48 49 benefit using a competing risk model; however, it is unknown if doing so will materially affect absolute risk reduction estimates attributable to anticoagulants. 50

51 We used patient-level data from 12 randomized trials of anticoagulants for atrial 52 fibrillation to determine if a competing risk model affects the measurement of absolute stroke

53	risk reduction. First, we compared the guideline-endorsed approach to measuring absolute risk
54	reduction (i.e., CHA <sub>2</sub> DS <sub>2</sub> -VASc score) to a competing risk model (i.e., Fine-Gray model <sup>15</sup> ).
55	Second, we determined if differences in expected stroke risk reduction between the guideline-
56	endorse $CHA_2DS_2$ -VASc approach and a competing risk model varied by life expectancy.
57	
58	METHODS
59	Study design and participants
60	We used patient-level data from the Atrial Fibrillation Investigators (AFI) database which

61 contains patient-level data from 12 published clinical trials where patients were randomized to full-dose oral anticoagulant, antiplatelets, or placebo. We focused on trials that established the 62 efficacy of oral anticoagulants; therefore, we did not include trials that compared two different 63 oral anticoagulants. We included the following trials: Atrial Fibrillation, Aspirin, and 64 Anticoagulation Study 1 (AFASAK-1).<sup>16</sup> AFASAK-2.<sup>17</sup> Boston Area Anticoagulation Trial for Atrial 65 Fibrillation (BAATAF),<sup>18</sup> Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA),<sup>19</sup> 66 Canadian Atrial Fibrillation Anticoagulation (CAFA),<sup>20</sup> European Atrial Fibrillation Trial (EAFT),<sup>21</sup> 67 Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation (PAATAF),<sup>22</sup> National 68 Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF),<sup>23</sup> the Stroke Prevention in 69 Atrial Fibrillation 1 (SPAF-1).<sup>24</sup> SPAF-2.<sup>25</sup> SPAF-3.<sup>26</sup> and Stroke Prevention in Non-rheumatic 70 Atrial Fibrillation (SPINAF).<sup>27</sup> We did not include patients with mitral stenosis and patients in 71 SPAF-1, EAFT, PATAF, and SPAF-3 who were deemed ineligible to receive anticoagulants 72 (trial details in Appendix 1 and Appendix 2). 73

## 74 Participant characteristics

75 Research coordinators and physicians collected patient characteristics before therapy initiation. While specific features varied from study to study, common elements included a 76 77 history of stroke or transient ischemic attack, hypertension or systolic blood pressure ≥160 78 mmHg or use of antihypertensives, diabetes, angina, myocardial infarction, peripheral vascular 79 disease, smoking, and congestive heart failure, and body mass index. History of myocardial 80 infarction was not collected in NASPEAF and peripheral vascular disease was not collected in AFASAK1, BAATAF, or BAFTA. Because history of myocardial infarction and peripheral 81 82 vascular disease were missing for all participants in specific trials, we assumed they were missing at random and imputed them in 20 datasets using chained equations.<sup>28</sup> We excluded 83 <1% of participants who were missing data otherwise collected in a given trial (Appendix 3). 84

85

#### 86 Treatment exposure

87 We examined all patients based on their treatment allocation (i.e., intention to treat). 88 Because studies have shown that antiplatelet and low-dose warfarin are ineffective thromboprophylaxis in AF,<sup>6</sup> we categorized all trial participants as being randomized to full-dose 89 90 anticoagulants or control. Patients randomized to placebo, antiplatelets, low-dose warfarin, or low-dose warfarin with aspirin were considered controls. AFASAK2, PAATAF, and SPAF3 used 91 92 low-dose warfarin and reported a mean international normalized ratio (INR) of < 1.5 supporting 93 their categorization as a control. While NASPEAF also had a low-dose anticoagulant arm, the mean INR was 2.0 which is considered therapeutic<sup>1</sup>; therefore, we excluded participants 94 95 randomized to the NASPEAF low-dose anticoagulant arm.

## 96 Outcome ascertainment

97	The primary outcome was ischemic stroke or systemic embolism. We detail outcome		
98	definitions by trial in Appendix 4. In general, trials defined ischemic stroke as a focal		
99	neurological deficit lasting >24 hours. All trials except AFASAK-1 required a CT or MRI showing		
100	the absence of blood. Systemic embolism was collected as an outcome in all but SPINAF and,		
101	by and large, defined as an embolism to internal organs or limbs and required evidence via		
102	angiography, surgery, or autopsy (Appendix 4). Patients were evaluated at 3- to 6-month		
103	intervals or when a clinical outcome event was suspected. Except in AFASAK-1, a central		
104	committee, blinded to intervention allocation, adjudicated all clinical events.		
105			
105 106	Life expectancy		
105 106 107	Life expectancy We estimated the life expectancy of each participant at the time of trial enrollment using		
105 106 107 108	Life expectancy We estimated the life expectancy of each participant at the time of trial enrollment using the life table method. <sup>29</sup> We started with gender- and enrollment year-specific life tables from the		
105 106 107 108 109	Life expectancy We estimated the life expectancy of each participant at the time of trial enrollment using the life table method. <sup>29</sup> We started with gender- and enrollment year-specific life tables from the U.S. Centers for Disease Control and Prevention. <sup>30</sup> These tables, generated from population		
105 106 107 108 109 110	Life expectancy We estimated the life expectancy of each participant at the time of trial enrollment using the life table method. <sup>29</sup> We started with gender- and enrollment year-specific life tables from the U.S. Centers for Disease Control and Prevention. <sup>30</sup> These tables, generated from population data, predict annual mortality rates stratified by age, sex, and year. The life table method uses		

each participant's life expectancy by adjusting the annual mortality rate for the additional

mortality risk associated with their comorbidities at the time of trial enrollment (**Appendix 5**).

114

## 115 Analysis

116 Our first analytic goal was to determine if using a competing risk framework generates 117 estimates of stroke risk reduction different from those of the guideline-endorsed CHA<sub>2</sub>DS<sub>2</sub>-VASc 118 model. To accomplish this and speak directly to guideline-recommended practice, we estimated 119 absolute risk reduction using the CHA<sub>2</sub>DS<sub>2</sub>-VASc score as the ACC/AHA/HRS guidelines

recommend.<sup>1,2</sup> Specifically, we assigned each patient an off-treatment risk of ischemic stroke or 120 121 systemic embolism corresponding to their CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Rates come from the 2012 study by Friberg et al., which used the Swedish Atrial Fibrillation cohort to validate off-treatment 122 123 thromboembolic rates corresponding to each CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>31</sup> These rates are used in patient-facing decision tools, online calculators, and decision analytic models.<sup>5,32,33</sup> To calculate 124 the absolute risk reduction, we multiplied the off-treatment stroke rate by 0.64, the guideline-125 cited efficacy of anticoagulants.<sup>1,6</sup> Using this procedure for each patient, we estimated the 126 annual absolute risk reduction; this precise method is endorsed by the ACC/AHA/HRS Atrial 127 Fibrillation management guidelines to estimate benefit.<sup>1</sup> Because patients and physicians prefer 128 to make anticoagulant decisions using a 1-to-5-year time horizon,<sup>5</sup> we extrapolated this annual 129 reduction over five years, accounting for the declining at-risk population (Appendix 6).<sup>34,35</sup> The 130 131 same approach is also used in decision aids.<sup>5</sup>

132 Next, we estimated the absolute risk reduction using the Fine-Gray extension of the Cox proportional hazards model, treating death unrelated to ischemic stroke or systemic embolism 133 as a competing event.<sup>11</sup> We fit a Fine-Gray model where time to ischemic stroke or systemic 134 embolism is a function of age (<65 years, 65-74 years, >75 years), gender, congestive heart 135 136 failure, diabetes, hypertension, prior stroke or transient ischemic attack, and vascular disease 137 stratified by randomization to oral anticoagulants. These the same predictors used in the 138 CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Then, we used the resulting treatment-stratified models to estimate the 139 cumulative incidence of ischemic stroke or systemic embolism for each participant given their 140 covariates at each study time point, assuming first they had been randomized to oral anticoagulants and then assuming they had been randomized to control (i.e., predicted 141 values).<sup>36,37</sup> The difference between the two estimates represented the ARR for a given patient 142 at a given time point. We determined the misestimation of the CHA<sub>2</sub>DS<sub>2</sub>-VASc method as the 143 144 difference between the ARR estimated by CHA<sub>2</sub>DS<sub>2</sub>-VASc and the ARR estimated by the

145	Competing Risk Model. We used the paired t-test to determine if the two methods produced		
146	statistically different estimates of benefit at each year after randomization.		
147	Our second analytic goal was to determine if life expectancy predicted magnitude in the		
148	$CHA_2DS_2$ -VASc model misestimation. To achieve this, we determined the association between		
149	life expectancy and misestimation of the $CHA_2DS_2$ -VASc method over a 3-year horizon. We		
150	chose 3 years since it is the midpoint between the 1-to-5 year horizon preferred by patients and		
151	physicians and has been used in prior anticoagulation decision analyses. <sup>5,38</sup> We examined		
152	misestimation of the $CHA_2DS_2$ -VASc method by decile of life expectancy at trial enrollment,		
153	hypothesizing that the misestimation would be greater at lower life expectancies.		
154	We performed all statistical analyses using SAS 9.4 (Cary, NC). The study protocol was		
155	approved by Institutional Review Boards at UCSF (21-34930) and MGH (2022P001783).		
156			
157	RESULTS		
158	Patient characteristics and overall event rates		
159	This study included 7933 patients from 12 randomized trials where 3407 (43%) were		
160	randomized to oral anticoagulation (Table 1). The median age was 73 years at enrollment, 36%		
161	were women, and the median $CHA_2DS_2$ -VASc score was 3 [IQR 2, 4]. At enrollment, the		
162	median life expectancy was 8 years [IQR 6, 12] (Appendix 7). Most patients (83%) ended the		
163	follow-up period without a clinical event (median 731 days; IQR 415, 1025). (Table 2). In these		
164	trials, 530 (7%) patients' first clinical event was an ischemic stroke or systemic embolism		

- 165 (median 334 days; IQR 120, 580). Additionally, 630 (8%) patients died before a stroke or
- 166 systemic embolism (median 457 days; IQR 216, 772).

### 167 **Comparison of absolute risk reduction estimates**

168	Relative to the Competing Risk Model, the $CHA_2DS_2$ -VASc model overestimated the
169	absolute risk reduction (ARR) of anticoagulants (Figure 1). As the time horizon increased, the
170	CHA2DS2-VASc estimate of median benefit increased linearly. In contrast, the Competing Risk
171	Model estimated a non-linear absolute risk reduction over time—while benefit increased over
172	time, it decelerated, i.e., absolute risk reduction grew by less each year. As a result, the
173	CHA <sub>2</sub> DS <sub>2</sub> -VASc model overestimated anticoagulation benefit as the time-horizon increased.
174	After 1 year, the $CHA_2DS_2$ -VASc model and the Competing Risk Model produced clinically
175	similar estimates of absolute risk reduction (median ARR 2.3% by $CHA_2DS_2$ -VASc estimate vs.
176	2.4% by Competing Risk Model, p<0.001). After 3 years, the $CHA_2DS_2$ -VASc-based ARR was
177	clinically and statistically larger than the ARR from the Competing Risk Model (median ARR
178	6.9% vs. 5.2%, p<0.001). This difference increased when absolute risk reduction was estimated
179	over a 5-year horizon (median ARR 11.2% vs. 6.3%, p<0.001).

We assess whether the observed discrepancy in ARR could be because the guidelines estimate of off-treatment stroke risk were produced in an external cohort and therefore were miscalibrated (**Appendix 9**). The sensitivity showed that recalibration to the AFI database did not meaningfully change the results presented in **Figure 1**.

184

#### 185 Life expectancy and misestimation of benefit

As life expectancy decreased, the  $CHA_2DS_2$ -VASc model increasingly overestimated the stroke and systemic embolism risk reduction attributable to anticoagulants in absolute and relative terms (**Figure 2**). The figure plots the absolute and relative difference between the 3year ARR estimated by the  $CHA_2DS_2$ -VASc model and the Competing Risk Model by life expectancy decile at trial enrollment. In the decile with the highest life expectancy (16 to 47

191 years), on average, over 3 years, the  $CHA_2DS_2$ -VASc model underestimated benefit by 1.2% 192 (95% CI 1.1% to 1.3%) in absolute terms and 42% (95% CI 40% to 45%) in relative terms. By 193 comparison, in the decile with the lowest life expectancy (1 to 4 years), on average over 3 194 years, the  $CHA_2DS_2$ -VASc model overestimated benefit by 5.9% (95% CI 5.6% to 6.1%) in 195 absolute terms and 91% (95% CI 87% to 95%) in relative terms.

196

#### 197 DISCUSSION

Using patient-level data from 12 randomized trials, we demonstrated that while 198 199 anticoagulants effectively reduce ischemic stroke and systemic embolism risk, failing to use a 200 competing risks framework resulted in a meaningful overestimation of treatment benefit. This 201 finding was most pronounced when risk reduction was estimated over a multi-year horizon. 202 Further, we showed that as life expectancy decreased, treatment benefit was increasingly overestimated. While those with the highest life expectancy may benefit more than guideline 203 204 estimates would suggest, benefit for those with the lowest life expectancy was strikingly 205 overestimated.

The study results directly apply to the AHA/ACC/HRS<sup>1,2</sup> and European Society of 206 Cardiology (ESC)<sup>3</sup> atrial fibrillation guidelines in which the cornerstone of anticoagulant 207 208 decision-making is estimating the absolute risk reduction. Guidelines ask clinicians to estimate 209 the off-treatment stroke risk using the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and to use that baseline risk to 210 infer the probable absolute risk reduction. Anticoagulants are recommended above a CHA<sub>2</sub>DS<sub>2</sub>-211 VASc score threshold—i.e., when the absolute risk reduction exceeds a threshold. Thus, if 212 clinical guidelines continue to recommend treatment using an absolute risk reduction threshold, 213 these results suggest guidelines should re-estimate benefit using a competing risk framework.

At the very least, guidelines should acknowledge that current methods overestimate benefits for those with limited life expectancy and when estimating benefits over a multi-year horizon.

216 The current study's findings should influence anticoagulant decision aids for patients 217 with atrial fibrillation. To advance anticoagulant shared decision-making, investigators and 218 professional societies have developed conversation aids that display a patient's risk of stroke 219 with and without anticoagulants. For example, the American College of Cardiology's 220 CardioSmart tool and the Mayo Clinic Anticoagulation Choice Decision Aid both display a pictogram of absolute risk with and without treatment to communicate treatment effects.<sup>4,5</sup> 221 222 These implementation tools are built to reflect clinical guidelines and do so faithfully. However, 223 both should note that benefit estimates are overstated for those with limited life expectancy and when benefit is estimated over a multi-year horizon. 224

225 These results also lend credence to physicians for whom advanced age, frailty, and 226 function-all significant determinants of life expectancy-factor in their anticoagulant decisionmaking.<sup>39,40</sup> Adults aged 65 years and older constitute 80% of all American adults with atrial 227 fibrillation.<sup>41</sup> Further, prior work indicates that many older adults with atrial fibrillation have 228 229 geriatric syndromes (e.g., dependency in activities of daily living) known to be associated with a reduced life expectancy.<sup>42,43</sup> In this study, we estimated life expectancy using basic medical 230 231 comorbidity data available in the trial database. Modern, more accurate tools go beyond 232 comorbidities using physical function, cognition, and self-reported health to estimate life expectancy.<sup>44,45</sup> Life expectancy estimates from such tools are routinely used to inform the risk 233 234 and benefits of interventions in older adults (e.g., cancer screening). Until guidelines formally 235 account for it, clinicians may consider using life expectancy to guide the discussion about the benefit of anticoagulants when treating older adults. This may be particularly relevant when 236 treating patients with both a limited life expectancy and borderline CHA<sub>2</sub>DS<sub>2</sub>-VASc scores. 237

238 Finally, these findings should inform the methods used to develop and validate future 239 stroke risk models. While the CHA<sub>2</sub>DS<sub>2</sub>-VASc score continues to be endorsed by U.S. and 240 European guidelines, investigators are actively developing a new generation of stroke risk 241 prediction models. Contemporary models like the ABC stroke risk score, CARS, and the ATRIA stroke model all outperform the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>46–48</sup> However, none used an analysis 242 243 framework that both accounts for the competing risk of death and changing risk over a multi-244 year horizon. The ABC model establishes a non-linear stroke risk by showing 3-year risk is not 245 simply three times the 1-year risk, findings that were redemonstrated in this paper. When 246 developing the ABC model, Hijazi et al. also conducted a sensitivity analysis comparing their model to a competing risk model.<sup>46</sup> They found a tight correlation when risk was estimated over 247 248 a 1-year horizon, results mirrored in this study. We expanded on their work by showing that this 249 correlation was weaker when using a longer time horizon (e.g., 3 years). More importantly, we 250 identified substantial heterogeneity—as life expectancy decreased, overestimation increased.

251 There are limitations to this study inherent to the data available and the study design. 252 First, this study relied on data from RCTs conducted between 1989 and 2007 and thus may be 253 only partially representative of contemporary patients with atrial fibrillation. Specific differences 254 include the risk of stroke and death from non-atrial fibrillation causes and the added safety of direct-acting anticoagulants.<sup>49</sup> This limitation is balanced by the fact that the AFI cohort is one of 255 256 the largest patient-level atrial fibrillation cohorts where anticoagulant treatment was randomized 257 against placebo and antiplatelets. The results were unaffected by selection bias that hampers 258 contemporary risk models developed in observational cohorts. More importantly, while dated, 259 these trials are the foundation upon which current guidelines recommend anticoagulants. Second, this study could not address the relationship between life expectancy and the potential 260 261 misestimation of anticoagulant harm. Specifically, the AF Investigators database does not 262 include inputs used in contemporary hemorrhage prediction tools (e.g., ATRIA bleed, HAS-

BLED). While it is important to consider the effect a competing risk framework may have on
estimating the risk of bleeding, current guidelines do not incorporate bleeding risk into treatment
recommendations. For example, for patients with scores above the CHA<sub>2</sub>DS<sub>2</sub>-VASc treatment
threshold, guideline recommendations do not change whether the bleeding risk is high or low.
Finally, because nationality was unavailable for study participants, we relied on U.S. life tables
to calculate life expectancy.

In summary, we showed that while oral anticoagulants were clearly effective, treatment benefit was overstated when using the guideline-endorsed approach because guidelines do not account for the competing risk of death and assume a constant growth in treatment benefit over time. Overestimation was most pronounced in patients with the lowest life expectancy and when benefit was estimated over a multi-year horizon. These findings should inform guidelines and decision aids, clinicians treating patients with limited life expectancy, and investigators developing stroke risk prediction models.

#### ACKNOWLEDGMENTS

We thank Dr. Sei Lee, Professor of Medicine at UCSF, for his valuable methodological feedback. Dr. Shah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Author contributions:** Dr. Shah had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors listed have contributed sufficiently to the project to be included as authors, and all those who are qualified to be authors are listed in the author byline.

**Conflict of Interest Disclosure:** Dr. Shah, Dr. Jeon, Dr. Boscardin, and Dr. Covinsky reported funding from the National Institute on Aging/National Institutes of Health related to the conduct of this study (noted below). Dr. Fang reported grants from the National Heart, Lung, and Blood Institute/National Institutes of Health during the conduct of the study (K24HL141354) and grants from Patient-Centered Outcomes Research Institute outside the submitted work. Dr. Singer was supported, in part, by the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital. He has received research support from Bristol Myers Squibb and consultancy fees from Bristol-Myers Squibb, Fitbit, Medtronic, and Pfizer. Professor Hobbs is, in part, supported by the NIHR (ARC OTV and MIC) and has received occasional consultancy fees from Bayer, BMS Pfizer, Novartis, and AZ unconnected to this study.

Funding: This study was funded by the NIA (K76AG074919, P30AG044281).

**Role of the Funder/Sponsor**: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data sharing: Researchers can apply to the AF Investigators for data access.

# REFERENCES

- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline
   for the Management of Patients With Atrial Fibrillation: A Report of the American College of
   Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart
   Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022
- January C, Wann L. Samuel, Calkins Hugh, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation*. 2019;140(2):e125-e151.
- 285 doi:10.1161/CIR.000000000000665
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and
   management of atrial fibrillation developed in collaboration with the European Association
   for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2021;42(5):373-498.
   doi:10.1093/eurheartj/ehaa612
- Atrial Fibrillation | CardioSmart American College of Cardiology. CardioSmart. Accessed
   December 23, 2020. http://www.cardiosmart.org/topics/atrial-fibrillation
- Zeballos-Palacios CL, Hargraves IG, Noseworthy PA, et al. Developing a Conversation Aid
   to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.
   *Mayo Clin Proc.* 2019;94(4):686-696. doi:10.1016/j.mayocp.2018.08.030
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke
   in Patients Who Have Nonvalvular Atrial Fibrillation. *Ann Intern Med.* 2007;146(12):857 867. doi:10.7326/0003-4819-146-12-200706190-00007
- Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. *Stat Med.* 2017;36(8):1203-1209. doi:10.1002/sim.7215
- Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? *Stat Med.* 2012;31(11-12):1089-1097. doi:10.1002/sim.4384
- Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. *Br J Cancer*. 2004;91(7):1229-1235.
   doi:10.1038/sj.bjc.6602102
- Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing Risk of Death: An Important Consideration in Studies of Older Adults. *J Am Geriatr Soc.* 2010;58(4):783-787. doi:10.1111/j.1532-5415.2010.02767.x
- Austin Peter C., Lee Douglas S., Fine Jason P. Introduction to the Analysis of Survival
   Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609.
   doi:10.1161/CIRCULATIONAHA.115.017719

- Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial
   Fibrillation on the Risk of Death: The Framingham Heart Study. *Circulation*.
- 315 1998;98(10):946-952. doi:10.1161/01.CIR.98.10.946
- Piccini Jonathan P., Hammill Bradley G., Sinner Moritz F., et al. Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007.
   *Circ Cardiovasc Qual Outcomes*. 2012;5(1):85-93.
- 319 doi:10.1161/CIRCOUTCOMES.111.962688
- Siontis KC, Gersh BJ, Weston SA, et al. Associations of Atrial Fibrillation After Noncardiac
   Surgery With Stroke, Subsequent Arrhythmia, and Death: A Cohort Study. *Ann Intern Med.* Published online July 26, 2022:M22-0434. doi:10.7326/M22-0434
- Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing
   Risk. J Am Stat Assoc. 1999;94(446):496-509. doi:10.2307/2670170
- Petersen P, Godtfredsen J, Boysen G, Andersen E, Andersen B. PLACEBO CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR
   PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL
   FIBRILLATION: The Copenhagen AFASAK Study. *The Lancet.* 1989;333(8631):175-179.
   doi:10.1016/S0140-6736(89)91200-2
- Gulløv AL, Koefoed BG, Petersen P, et al. Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern Med.* 1998;158(14):1513-1521. doi:10.1001/archinte.158.14.1513
- Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Singer DE, Hughes
   RA, et al. The effect of low-dose warfarin on the risk of stroke in patients with
   nonrheumatic atrial fibrillation. *N Engl J Med*. 1990;323(22):1505-1511.
   doi:10.1056/NEJM199011293232201
- Mant J, Hobbs FR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *The Lancet*.
   2007;370(9586):493-503. doi:10.1016/S0140-6736(07)61233-1
- 20. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial
  fibrillation anticoaguiation (CAFA) study. *J Am Coll Cardiol*. 1991;18(2):349-355.
  doi:10.1016/0735-1097(91)90585-W
- EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *The Lancet*.
   1993;342(8882):1255-1262. doi:10.1016/0140-6736(93)92358-Z
- Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial
  thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled
  trial comparing two intensities of coumarin with aspirin. *BMJ*. 1999;319(7215):958-964.
  doi:10.1136/bmj.319.7215.958

- Pérez-Gómez F, Alegría E, Berjón J, et al. Comparative effects of antiplatelet,
  anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial
  fibrillation: A randomized multicenter study. *J Am Coll Cardiol*. 2004;44(8):1557-1566.
  doi:10.1016/j.jacc.2004.05.084
- Preliminary Report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med.* 1990;322(12):863-868. doi:10.1056/NEJM199003223221232
- Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention
   of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *The Lancet.* 1994;343(8899):687-691. doi:10.1016/S0140-6736(94)91577-6
- Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke
   Prevention in Atrial Fibrillation III randomised clinical trial. *The Lancet*.
   1996;348(9028):633-638. doi:10.1016/S0140-6736(96)03487-3
- 27. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke
   associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in
   Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med.* 1992;327(20):1406-1412.
   doi:10.1056/NEJM199211123272002
- 28. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med.* 2011;30(4):377-399. doi:https://doi.org/10.1002/sim.4067
- 371 29. Method for Constructing Complete Annual U.S. Life Tables. National Center for Health
   372 Statistics; 1999:36.
- 373 30. The Berkeley Mortality Database. Accessed November 3, 2021. http://bmd.mortality.org/
- Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic
   stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation
   cohort study. *Eur Heart J.* 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488
- 377 32. CHA<sub>2</sub>DS<sub>2</sub>-VASc Score for Atrial Fibrillation Stroke Risk MDCalc. Accessed October 11,
   378 2022. https://www.mdcalc.com/calc/801/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk
- 379 33. Eckman MH, Wise RE, Naylor K, et al. Developing an Atrial Fibrillation Guideline Support
   Tool (AFGuST) for shared decision making. *Curr Med Res Opin.* 2015;31(4):603-614.
   doi:10.1185/03007995.2015.1019608
- 382 34. Miller DK, Homan SM. Determining Transition Probabilities: Confusion and Suggestions.
   383 Med Decis Making. 1994;14(1):52-58. doi:10.1177/0272989X9401400107
- 384 35. Rothman KJ. *Epidemiology: An Introduction*. Oxford University Press; 2002.
   385 https://books.google.com/books?id=f3gltAEACAAJ
- 386 36. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating Model-Adjusted Risks, Risk
   387 Differences, and Risk Ratios From Complex Survey Data. *Am J Epidemiol.* 388 2010;171(5):618-623. doi:10.1093/aje/kwp440

- 389 37. Graubard BI, Korn EL. Predictive Margins with Survey Data. *Biometrics*. 1999;55(2):652 390 659. doi:10.1111/j.0006-341X.1999.00652.x
- 38. Shah Sachin J., Singer Daniel E., Fang Margaret C., Reynolds Kristi, Go Alan S., Eckman
   Mark H. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial
   Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2019;12(11):e006212.
- 394 doi:10.1161/CIRCOUTCOMES.119.006212
- 395 39. Ashburner JM, Atlas SJ, Khurshid S, et al. Electronic physician notifications to improve
   396 guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. *J Gen* 397 *Intern Med.* Published online August 3, 2018. doi:10.1007/s11606-018-4612-6
- 40. McGrath ER, Go AS, Chang Y, et al. Use of Oral Anticoagulant Therapy in Older Adults
  with Atrial Fibrillation After Acute Ischemic Stroke. *J Am Geriatr Soc.* 2017;65(2):241-248.
  doi:10.1111/jgs.14688
- 41. Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults:
  National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-2375.
  404 doi:10.1001/jama.285.18.2370
- 42. Shah SJ, Fang MC, Jeon SY, Gregorich SE, Covinsky KE. Geriatric Syndromes and Atrial
  Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of
  Older Americans. *J Am Geriatr Soc.* 2021;69(2):349-356. doi:10.1111/jgs.16822
- 43. Kane RL, Shamliyan T, Talley K, Pacala J. The Association Between Geriatric Syndromes and Survival. *J Am Geriatr Soc.* 2012;60(5):896-904. doi:10.1111/j.1532-5415.2012.03942.x
- 44. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and Validation of a Prognostic
  Index for 4-Year Mortality in Older Adults. *JAMA*. 2006;295(7):801-808.
  doi:10.1001/jama.295.7.801
- 414
  45. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to Predict 5-Year
  415 Mortality of Community-Dwelling Adults Aged 65 and Older Using Data from the National
  416 Health Interview Survey. *J Gen Intern Med.* 2009;24(10):1115-1122. doi:10.1007/s11606417 009-1073-y
- 46. Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke
  risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. *Eur Heart*J. 2016;37(20):1582-1590. doi:10.1093/eurheartj/ehw054
- 47. Lee CJY, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients
  with atrial fibrillation using a risk factor-based approach. *Eur Heart J Cardiovasc Pharmacother*. 2021;7(FI1):f3-f10. doi:10.1093/ehjcvp/pvaa063
- 424
  48. Singer DE, Chang Y, Borowsky LH, et al. A New Risk Scheme to Predict Ischemic Stroke
  425
  426 and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. J
  426 Am Heart Assoc. 2013;2(3):e000250. doi:10.1161/JAHA.113.000250

- 427 49. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new
- 428 oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of 429 randomised trials. *The Lancet.* 2014;383(9921):955-962.

n=7933

Age, years (median [IQR])	73 [67, 78]	
Gender		
Male	5040 (64%)	
Female	2893 (36%)	
Diabetes		
No	6780 (85%)	
Yes	1153 (15%)	
Hypertension		
No	4049 (51%)	
Yes	3884 (49%)	
Congestive heart failure		
No	5533 (70%)	
Yes	2400 (30%)	
Prior stroke		
No	6413 (81%)	
Yes	1520 (19%)	
Angina		
No	6566 (83%)	
Yes	1367 (17%)	
Prior myocardial infarction		
No	6514 (82%)	
Yes	876 (11%)	
Missing*	543 (7%)	
Peripheral vascular disease		
No	5109 (64%)	
Yes	429 (5%)	
Missing <sup>†</sup>	2395 (30%)	
Body mass index kg/m <sup>2</sup> (median [IQR])		
BMI among those with data	26 [24, 29]	
Missing <sup>‡</sup>	2070 (26%)	
Smoking status		
Never smoker	2427 (31%)	
Former smoker	1843 (23%)	
Current smoker	790 (10%)	
Missing <sup>§</sup>	2873 (36%)	

# Table 1: Characteristics of patients with atrial fibrillation in 12 randomized trials

Characteristic

CHA<sub>2</sub>DS<sub>2</sub>-VASc score

Score (median [IQR])	3 [2, 4]
Missing⁻	2938 (37%)
Trial	
AFASAK1	1002 (13%)
AFASAK2	677 (9%)
BAATAF	420 (5%)
BAFTA	973 (12%)
CAFA	375 (5%)
EAFT	661 (8%)
NASPEAF	543 (7%)
PATAF	364 (5%)
SPAF1	208 (3%)
SPAF2	1098 (14%)
SPAF3	1044 (13%)
SPINAF	568 (7%)
Randomized study arm assignment	
Warfarin	3407 (43%)
Control <sup>¶</sup>	4526 (57%)

#### Legend

AFASAK - Atrial Fibrillation, Aspirin, and Anticoagulation Study; BAATAF - Boston Area Anticoagulation Trial for Atrial Fibrillation; BAFTA - Birmingham Atrial Fibrillation Treatment of the Aged Study; CAFA - Canadian Atrial Fibrillation Anticoagulation; EAFT - European Atrial Fibrillation Trial; PAATAF - Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation; NASPEAF - National Study for Prevention of Embolism in Atrial Fibrillation; SPINAF - Stroke Prevention in Non-rheumatic Atrial Fibrillation

\* History of myocardial infarction was not available for NSPEAF trial participants

† History of peripheral vascular disease was not available for AFASAK1, BAATAF, or BAFTA trial participants

‡ Height and weight were not available for BAATAF or AFASAK2 trial participants

§ Smoking status was not available for AFASAK1, CAFA, or BAFTA participants. In EAFT, data collection did not distinguish between former and never smokers

□ CHA<sub>2</sub>DS<sub>2</sub>-VASc scores are for those with complete cases. It excludes 2395 participants enrolled in trials where peripheral vascular disease data are not available, and 543 participants enrolled in trials where history of myocardial infarction was not available.

¶ Control includes those assigned placebo, aspirin, low-dose warfarin, or low-dose warfarin an aspirin. Patients enrolled in SPAF3 and AFASAK2 and assigned to low-dose warfarin had a mean internal normalized ratio (INR) of < 1.5 supporting their categorization as a control. Patients enrolled in NASPEAF and randomized to low-dose anticoagulant had a mean INR of 2.0 and were therefore not included as a control.

Since missing data were missing for entire trials, they were assumed to be missing completely at random.

# Table 2: Trial outcomes, rates and follow-up time

First sliniss, sutsame	$\mathbf{F}_{1}$	Days from randomization,
First clinical outcome	Events (%)	median (IQR)
Ischemic stroke or systemic embolism	530 (7%)	334 (120, 580)
Systemic bleed	175 (2%)	413 (163, 731)
Intracranial hemorrhage	29 (0%)	300 (201, 620)
Death, all-cause	630 (8%)	457 (216, 772)
Study end without a clinical event	6569 (83%)	731 (415, 1025)



# Figure 1: Estimated median absolute risk reduction by CHA<sub>2</sub>DS<sub>2</sub>-VASc model compared with Competing Risk Model

#### Legend

For each patient in the cohort, we estimate the absolute risk reduction attributable to oral anticoagulation annually for 5 years using the  $CHA_2DS_2$ -VASc model and again using a Fine-Gray model, a survival model that accounts for the competing risk of death. We plot the median benefit at each time point. We graphed the median ARR because the  $CHA_2DS_2$ -VASc model produces discrete estimates of benefit (i.e., not normally distributed). Data are presented as a table in **Appendix 10**. Component on- and off-treatment cumulative incidence rates also displayed in **Appendix 10**.

Figure 2: Misestimation of Stroke Risk Reduction by CHA<sub>2</sub>DS<sub>2</sub>-VASc score at 3 years,



## (A) Absolute misestimation

Decile of life expectancy (range)

## (B) Relative misestimation



Decile of life expectancy (range)

#### Legend

Absolute misestimation is defined as: ARR<sub>CHA2DS2-VASc</sub> – ARR<sub>Competing Risk Model</sub>.

Relative misestimation is defined as:  $ARR_{CHA2DS2-VASc} / ARR_{Competing Risk Model} - 1$ .

The dot represents the mean overestimation, and the error bars represent the 95% confidence interval of the mean. The misestimation of absolute risk reduction (ARR) is calculated for each patient as the difference between the ARR computed by the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and the ARR computed by the Fine-Gray model, a survival model that accounts for the competing risk of death. Positive numbers represent the overestimation of the CHA<sub>2</sub>DS<sub>2</sub>-VASc model. Tabular results can be found in **Appendix 11**.